首页> 美国卫生研究院文献>Cancers >ZEB1 in Pancreatic Cancer
【2h】

ZEB1 in Pancreatic Cancer

机译:ZEB1在胰腺癌中

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pancreatic cancer is one of the most malignant human neoplasias. On the molecular level, epithelial-mesenchymal transition (EMT) has been demonstrated to contribute to the malignant phenotype of pancreatic cancer cells. ZEB1 is a transcriptional repressor that has been identified as an inducer of EMT. A negative feedback loop between ZEB1 and microRNA-200c has been shown to regulate this EMT induction in various models. With respect to pancreatic cancer, primary effects of EMT comprise increased local and distant tumor cell dissemination. Another recently described feature of the EMT is the acquisition of cancer stem cell traits. For pancreatic cancer cells, antagonism between ZEB1 and stemness-inhibiting micro-RNAs has been demonstrated to contribute to this process, providing experimental support for the migrating cancer stem cell (MCSC) hypothesis. ZEB1 has also been shown to be associated with drug resistance of pancreatic cancer cells. This article reviews the biological functions of ZEB1 with a focus on pancreatic cancer.
机译:胰腺癌是人类最恶性的肿瘤之一。在分子水平上,上皮-间质转化(EMT)已被证明有助于胰腺癌细胞的恶性表型。 ZEB1是一种转录阻遏物,已被确定为EMT的诱导物。在各种模型中,ZEB1和microRNA-200c之间的负反馈回路已证明可调节这种EMT诱导。对于胰腺癌,EMT的主要作用包括增加局部和远处肿瘤细胞的扩散。 EMT的另一个最近描述的特征是癌症干细胞性状的获得。对于胰腺癌细胞,ZEB1和抑制干性的微RNA之间的拮抗作用已被证明有助于此过程,为迁移的癌症干细胞(MCSC)假设提供了实验支持。 ZEB1也已被证明与胰腺癌细胞的耐药性有关。本文综述了ZEB1的生物学功能,重点是胰腺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号